* ARACLON BIOTECH gave special emphasis to the outstanding results obtained in its pilot study with the beta amyloid blood testing kit (ABtest 40 and 42), as a possible tool for diagnosing early-stage AD.
This is an international congress for the
pharmaceutical and biotechnological industry, held in San Francisco in
September and in which the Spanish biotechnology has, for the first time,
its own stand.
Throughout 2009 the vaccine will start regulatory pre-clinical development and Araclon Biotech expects to start clinical trials on humans at the end of the coming year.
This is the first European Patent for the biotechnology company Araclon Biotech, and one of the few awarded each year to Spanish companies in the sector.